MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

(±)-Zanubrutinib

CAS No. : 1633350-06-7

MCE 站：(±)-Zanubrutinib

产品活性：(±)-Zanubrutinib ((±)-BGB-3111) 是一种有效选择性的，具有口服活性的 Bruton's 酪氨酸激酶 (Btk) 抑制剂。

研究领域：Protein Tyrosine Kinase/RTK

作用靶点：Btk

In Vitro: In both biochemical and cellular assays, (±)-Zanubrutinib ((±)-BGB-3111) demonstrates nanomolar Btk inhibition activity. In several MCL and DLBCL cell lines, (±)-Zanubrutinib inhibits BCR aggregation-triggered Btk autophosphorylation, blocks downstream PLC-γ2 signaling, and potently inhibits cell proliferation. In comparison with PCI-32765, (±)-Zanubrutinib shows much more restricted off-target activities against a panel of kinases, including ITK.

In Vivo: (±)-Zanubrutinib induces dose-dependent anti-tumor effects against REC-1 MCL xenografts engrafted either subcutaneously or systemically via tail vein injection in mice. In the subcutaneous xenografts. Preliminary 14-day toxicity study in rats shows that (±)-Zanubrutinib is very well tolerated and maximal tolerate dose (MTD) is not reached when it is dosed up to 250mg/kg/day.

相关产品：Covalent Screening Library Plus  |  Bioactive Compound Library Plus  |  Kinase Inhibitor Library  |  Protein Tyrosine Kinase Compound Library  |  Anti-Cancer Compound Library  |  Covalent Screening Library  |  Orally Active Compound Library  |  Anti-Blood Cancer Compound Library  |  Ibrutinib-biotin  |  CG-806  |  LFM-A13  |  Ibrutinib deacryloylpiperidine  |  PCI 29732  |  Acalabrutinib D4

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。